WUXI, China — March 11, 2026
LabConnect, a global provider of technology-driven central laboratory services for clinical trials, announced the opening of a new laboratory facility in Wuxi, China, significantly expanding its global clinical research infrastructure. The new site is designed to strengthen LabConnect’s ability to support international clinical trials, biospecimen logistics, and laboratory data management, addressing the increasing complexity and geographic scale of modern drug development studies. The facility’s grand opening included a ceremonial ribbon-cutting event attended by company leaders, regional partners, and members of the clinical research community, highlighting the organization’s commitment to advancing global clinical trial capabilities in Asia and beyond.
Expanding Global Infrastructure for Clinical Trials
The Wuxi facility represents a strategic expansion of LabConnect’s global central laboratory network, enabling the company to deliver integrated laboratory testing, biospecimen management, and clinical trial logistics services to pharmaceutical and biotechnology sponsors worldwide. As clinical trials increasingly span multiple regions and patient populations, centralized laboratory capabilities have become critical to ensuring consistent testing methodologies, standardized data collection, and regulatory-compliant sample handling.
The new site is located in the Xinwu District of Wuxi, a rapidly growing hub for life sciences and pharmaceutical research. By establishing a presence in this region, LabConnect aims to provide localized laboratory services while maintaining global quality standards, helping sponsors manage cross-border clinical trials more efficiently. The facility also strengthens the company’s ability to coordinate sample collection, storage, and shipment across international research sites, ensuring that biospecimens reach testing laboratories with complete chain-of-custody tracking and regulatory compliance.
The expansion reflects the increasing demand for specialized central laboratory services in complex clinical studies, including oncology, rare diseases, and cell and gene therapy trials. Through its global infrastructure, LabConnect supports pharmaceutical sponsors with advanced testing capabilities, data integration systems, and laboratory logistics solutions designed to accelerate clinical development timelines.
Advertisement
Technology-Driven Laboratory Services and Sample Management
LabConnect’s operational model focuses on providing technology-enabled laboratory coordination and biospecimen logistics, allowing pharmaceutical and biotechnology companies to streamline laboratory processes across geographically dispersed clinical trials. The Wuxi facility will play a key role in delivering clinical trial kit building, advanced sample tracking, and biorepository services, ensuring that biological samples collected from trial participants are handled according to strict quality and regulatory standards.
Modern clinical trials require the management of large volumes of biological samples, complex testing protocols, and extensive laboratory data streams, making centralized laboratory management essential for maintaining consistency and accuracy across research sites. LabConnect’s technology-driven infrastructure enables sponsors to integrate laboratory data from multiple testing partners, manage specimen workflows, and maintain complete visibility across the clinical trial lifecycle.
The new facility also supports biospecimen storage and management services, which are critical for long-term clinical studies that require sample preservation for future analysis. These capabilities enable researchers to conduct retrospective biomarker studies and precision medicine analyses, supporting the growing role of molecular diagnostics and personalized medicine in clinical research.
By combining advanced logistics systems, laboratory coordination technology, and specialized biospecimen services, LabConnect aims to improve the efficiency and reliability of clinical trials conducted across multiple international research sites.
Strengthening Asia-Pacific Collaboration in Clinical Research
The expansion into Wuxi also reflects LabConnect’s commitment to strengthening its presence in the Asia-Pacific region, where clinical research activity continues to grow rapidly. Pharmaceutical and biotechnology companies increasingly conduct trials in Asia to access diverse patient populations, specialized research institutions, and expanding regulatory frameworks that support innovative drug development.
Through its new facility, LabConnect can provide localized expertise and operational support for clinical trial sponsors conducting studies in China and neighboring markets, while maintaining seamless integration with its global laboratory network. This regional capability enables sponsors to manage multinational trials more efficiently, ensuring that laboratory testing, biospecimen logistics, and regulatory compliance requirements are consistently maintained across all participating research sites.
The Wuxi expansion also strengthens collaboration between clinical research organizations, laboratory service providers, and pharmaceutical sponsors, enabling faster data generation and more efficient clinical study execution. By integrating advanced technology platforms with global logistics expertise, LabConnect continues to position itself as a strategic partner for pharmaceutical and biotechnology companies conducting complex international clinical trials.
As the clinical research landscape evolves toward larger, more globally distributed trials, infrastructure investments such as the Wuxi facility will play an increasingly important role in supporting next-generation drug development programs. Through its expanding global network, LabConnect aims to accelerate the path from clinical discovery to regulatory approval, helping deliver innovative therapies to patients around the world.
z
Source: LabConnect press release
